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Abstract
 Psychosis is a common and debilitating side effect of long-termBackground:
dopaminergic treatment of Parkinson disease (PD). While clozapine is an
effective treatment, the need for blood monitoring has limited its first-line use.  
 Since olanzapine shows similar receptor affinity to clozapine, weObjective:
hypothesized that it might be an effective alternative to clozapine for treatment
of drug-induced psychosis (DIP) in PD, and that lower doses than usual might
make it tolerable. 
 In 1998-2003 we conducted a four-week, double-blind,Methods:
placebo-controlled, parallel group, fixed-dose trial of olanzapine (0, 2.5mg, or
5mg) in 23 PD patients with DIP while allowing for clinically realistic dose
adjustments of dopaminomimetic mid-study. The primary outcome measures
were Brief Psychiatric Rating Scale (BPRS) ratings scored from videotaped
interviews after study termination by an observer blinded to dose assignment
and to interview timing, and CGI (Clinical Global Impression). The Unified
Parkinson’s Disease Rating Scale motor subscale (UPDRS) was the primary
measure of tolerability.
 Intention-to-treat analysis found no significant differences amongResults:
treatment groups in study completion or serious adverse events. However, a
disproportionate number of olanzapine vs. placebo subjects reported mild side
effects (p<0.04), many citing motor worsening. Fourteen patients completed
the study (seven on placebo, two on 2.5mg olanzapine, five on 5mg
olanzapine). In study completers, analysis by repeated measures ANOVA
revealed no significant difference between olanzapine and placebo groups in
BPRS psychosis reduction (p=0.536), parkinsonism (p=0.608), or any other
measured parameters (CGI, MMSE, Beck Depression Inventory, Hamilton
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 This study adds to other evidence that olanzapine is ineffectiveConclusion:
in treating medication-induced psychosis in Parkinson disease.
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Introduction
Drug-induced psychosis (DIP) is a significant and disabling 
complication of long-term treatment of Parkinson disease 
(PD), affecting a large minority of PD patients receiving chron-
ic dopaminergic therapy1. Visual hallucinations are the most 
commonly reported psychotic phenomena in this population, 
with auditory, tactile, somatic, and olfactory hallucinations 
being much less common. Delusions, when they occur, often 
antedate visual hallucinations and commonly are paranoid or 
persecutory in nature2,3. In addition to the increased caregiver 
burden caused by psychosis and its sequelae, hallucinations in 
the context of chronically treated PD tend to be progressive 
in nature, resulting in increased propensity for nursing home 
placement and subsequent higher mortality4,5. These sober-
ing associations suggest aggressive management of DIP in this 
population. However, either dose reduction of antiparkinsoni-
an medications or addition of traditional neuroleptics usually 
increases parkinsonian motor disabilities. Atypical antipsychot-
ics, with their comparatively lower incidence of parkinsonism 
in schizophrenia, have potential advantages for treatment of 
hallucinations in this sensitive population1.
Until recently, the only treatment proven with randomized, 
placebo-controlled studies to reduce DIP has been clozapine, 
an agent that does not worsen motor function6–8. Despite these 
favorable data, use of clozapine has been limited secondary to 
its rare but potentially serious risk of agranulocytosis and the 
consequent necessity for frequent blood draws1. Thus alterna-
tive treatments have been eagerly sought.
Quetiapine has become the most commonly prescribed antip-
sychotic in DIP9. Although double-blind, placebo-controlled 
trials of quetiapine in PD confirmed it is well tolerated in terms 
of motor side effects, it has not proven significantly more effec-
tive than placebo in treating psychosis10–15, and a head-to-head 
comparison found clozapine superior to quetiapine16. Ziprasi-
done showed some benefit in open-label experience17, including 
in a random-assignment open comparison to clozapine18. How-
ever, ziprasidone can cause motor side effects in PD and is not 
generally considered standard therapy for DIP1,19. Other treat-
ments, such as ondansetron, acetylcholinesterase inhibitors, 
and electroconvulsive therapy are supported by limited data 
in idiopathic Parkinson disease but are generally not viewed 
as first-line therapy1,19. Recently, a phase III clinical trial of a 
serotonin 5HT2A inverse agonist, pimavanserin, showed benefit 
over placebo, but the drug will not be available in the U.S. at 
least until late 201420–22.
Clozapine’s antipsychotic efficacy is often attributed to its D4 
receptor antagonism. It is also posited that its robust 5HT2A re-
ceptor antagonism, especially in relation to its relatively weaker 
D2 receptor blockade, actually increases dopamine transmis-
sion in prefrontal cortical and nigrostriatal projections23. This 
may account for the cognitive improvement as well as paucity 
of extrapyramidal adverse events observed in clozapine-treated 
patients with dopaminomimetic-induced psychosis23,24. Olan-
zapine, therefore, with its ostensibly similar receptor binding 
profile to clozapine at D2, D4, and serotonergic receptors (es-
pecially 5HT2A and 5HT2C), and muscarinic sites, provides a 
theoretically encouraging alternative to clozapine in this fragile 
population25.
An initial open study of olanzapine in Parkinson disease revealed 
antipsychotic benefit without motor deterioration when drug 
dosage was optimized in a slow titration (mean daily dose at end 
of study was 6.5mg) and dopaminomimetic dose adjustments 
were allowed26. Aarsland and colleagues replicated these findings 
in a relatively more challenging population of Parkinson dis-
ease patients with and without dementia27. Several other small, 
open-label studies of olanzapine, however, have demonstrated 
antipsychotic benefit but at the expense of intolerable worsen-
ing of gait and bradykinesia, frequently leading to premature 
termination of the drug28–30. Another small open-label trial and 
case report series suggested unacceptable Parkinsonian motor 
deterioration in the context of dubious antipsychotic effica-
cy31,32. Later, two double-blind placebo-controlled trials revealed 
equivocal antipsychotic benefit and problematic motor decline 
in PD patients with DIP treated with 2.5–15mg/day olanzapine 
(mean final doses 4.1–4.6mg/day)33,34. As a result, experts have 
recommended against the use of olanzapine in PD1,19.
None of these studies, however, were parallel-group fixed-dose 
trials, and some allowed for neuroleptic dose in the same range 
as approved for schizophrenia; experience with clozapine sug-
gests that an effective antipsychotic dose in PD is often an or-
der of magnitude less than that typical for schizophrenia treat-
ment. In addition, the two double-blind placebo-controlled 
trials did not permit adjustments of subjects’ dopaminomi-
metics, which might have alleviated motoric side effects. Final-
ly, some of the studies cited were terminated prematurely due 
to side effects. Given that the only marketed drug for which 
efficacy has been shown is clozapine, demonstrating efficacy 
for an alternative agent would be important, and a fixed low 
dose of olanzapine (2.5mg/day) may allow a reasonably low 
incidence of side effects if dopaminomimetic dose adjustments 
are allowed. We discuss here the findings of a double-blind, 
placebo-controlled study of fixed, low-dose olanzapine for 
treatment of DIP in the context of flexible dopaminomimetic 
dosing. The hypothesis was that olanzapine given in this fash-
ion would reduce DIP in patients with idiopathic PD signifi-
cantly more than would a placebo, without causing intolerable 
motor worsening.
Methods and materials
The completed CONSORT checklist35,36 and the original study 
protocol are available in the Data Files.
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Ethics statement
All patients gave written informed consent to participate in the 
study, which was approved by the Washington University Hu-
man Studies Committee (approval # 97-0366). In most cases 
an appropriate surrogate decision maker also consented. FDA 
approval was through IND # 53,556. This trial concluded in 
2003, so it is exempt from the current ICMJE requirement of 
prospectively registering clinical trials.
Patient selection
Twenty-four patients were recruited from the Washington 
University Movement Disorders Center from February 1998 
to October 2003. Patients were examined by a movement dis-
orders specialist and diagnosed with idiopathic PD based on 
presence of at least two of three cardinal manifestations of the 
disease (rigidity, bradykinesia, rest tremor), response to levo-
dopa or a dopamine agonist, and absence of historical or exam-
ination features suggesting secondary parkinsonism. Subjects 
were treated with levodopa and were experiencing clinically sig-
nificant hallucinations or delusions, as judged by their treating 
neurologist or psychiatrist and by the investigator (KJB). Sub-
jects were required to be over 30 years old and have a caregiver 
who could provide a reliable report. At study entry, patients 
were required to be treated with the lowest clinically acceptable 
dose of dopaminomimetic. Patients treated only with a dopa-
mine agonist were not entered in the study, as it was deemed 
more clinically appropriate to try a switch to levodopa before 
adding an antipsychotic. Exclusion criteria included a Folstein 
Mini-Mental State Examination (MMSE) score < 2237, preg-
nancy, concurrent diagnosis of delirium (unless clearly ex-
plained by dopaminomimetics), catatonia or neuroleptic ma-
lignant syndrome (NMS)-like syndrome, other confounding 
central nervous system (CNS) illness or systemic illness with 
potential CNS effects, antipsychotic use within the last month 
predating study enrollment (within the past six months for de-
pot neuroleptics), history of olanzapine sensitivity, or any ex-
pectation of significant medical or surgical intervention within 
six weeks after enrollment. Subjects were also excluded if sever-
ity of psychosis warranted hospitalization or if, in the investiga-
tor’s judgment, psychosis severity would have made randomiza-
tion to placebo inappropriate.
Treatment protocol
Patients were randomized 1:1:1 to treatment with placebo or 
either of two doses of olanzapine. At study initiation, treat-
ment groups consisted of a placebo arm, a 5mg arm, in which 
patients received this dosage nightly throughout the four weeks 
of investigation, and a 10mg arm, in which patients received 
5mg for the first week and 10mg thereafter. Subjects received 
matched tablets or capsules provided by Lilly Research Labo-
ratories (Indianapolis, IN), who provided the investigator with 
sealed, sequentially numbered envelopes containing the medi-
cation identity for each subject. The envelopes were not opened 
until after all data were collected and reviewed for accuracy, and 
after all decisions about statistical analysis were final, so that 
both investigators and patients were blind to intervention as-
signment. The randomization was done by Lilly. KJB enrolled 
subjects and patients were assigned to treatment packages 
sequentially by enrollment date.
After the first five patients were enrolled, an interim safety anal-
ysis was conducted by a reviewer otherwise not involved in the 
study, in light of reports published since the study initiation 
that higher olanzapine doses caused intolerable exacerbation of 
parkinsonism in PD. Though serious adverse events were no 
more common in the treatment groups than in the placebo 
group, it was decided at this time that the two active treatment 
arms would be changed to fixed doses of 2.5mg and 5mg olan-
zapine, maintained throughout the four weeks of study. New 
treatment packages were received and the blind was maintained 
until after data analysis, as above. No other changes to the pro-
tocol were made. See Table 1 for a summary of the final study 
design. The study was planned for 10 subjects in each of three 
dose arms. This would produce 90% power (at alpha = 0.05) 
to detect a change of the magnitude and variability seen in the 
Wolters et al.26 report.
Subjects received a baseline evaluation that involved a full 
psychiatric, neurologic, and medical history and examina-
tion, CGI (Clinical Global Impression) by MD38, PDQ-39, a 
self-rated quality-of-life measure for PD39, videotaped inter-
view for later BPRS (Brief Psychiatric Rating Scale) rating 
blind to drug dose and blind to which visit was being rated40, 
Schwab-England ADL assessment41, UPDRS (Unified Parkin-
son’s Disease Rating Scale), section III (motor)42, MMSE37, 
HDRS (Hamilton Depression Rating Scale)43, BDI (Beck De-
pression Inventory)44, and patient/caretaker reported hours and 
quality of sleep. Repeated measures at the two-week interim 
visit and the final four-week evaluation included CGI (by MD, 
patient, and caretaker), videotaped interview for later blinded 
BPRS, Schwab-England ADL assessment, UPDRS, MMSE, 
PDQ-39, BDI, sleep questionnaire, and pill counts. All assess-
ments were done at Washington University Medical Center.
Primary efficacy measures were CGI scores and BPRS ratings 
of psychosis. At each visit, the coordinator interviewed the pa-
tient during videotaping using a semi-structured interview de-
signed to facilitate later scoring of psychopathology using the 
BPRS40,45,46. After all subjects had completed participation, the 
videotaped segments were edited to remove references to date 
or study visit. Author KJB in consultation with a BPRS expert 
(John G Csernansky, MD) wrote rules for rating “motor retar-
dation” and other BPRS items potentially influenced by par-
kinsonism (see Supplementary materials), and trained author 
MJN in BPRS ratings. Videotaped segments were reviewed in 
random order by MJN, who was unaware of drug assignment 
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or treatment duration at the time of the visit. BPRS ratings 
used the anchored BPRS and each item was scored from 1–740. 
Secondary efficacy measures included the PDQ-39, ADL as-
sessments (Schwab-England and UPDRS), BDI, and sleep log. 
Primary safety measures were UPDRS motor ratings, sleep logs, 
and MMSE in addition to clinical review of systems.
Statistical analysis
Prior to unblinding of drug codes, the decision was made to 
analyze data from weeks 0–2 and weeks 2–4 separately. This 
a priori decision was made since adjustment of dopaminomi-
metics was allowed at the interim (week 2) visit. Change from 
0 to 2 weeks was chosen to be the primary test of efficacy. An 
intention-to-treat (ITT) analysis was performed on all enrolled 
subjects. However, since some subjects dropped out without 
completing outcome measures at a follow-up visit, the ITT 
analysis was limited to between-group comparisons of dropout 
rate, serious adverse events, and reported worsening of parkin-
sonism or other side effects judged to be at least mild in se-
verity. Adverse events, side effects, and study withdrawal were 
compared between groups using the chi-squared test.
For those subjects with data at both time points of an epoch, 
primary and secondary efficacy measures were tested separately 
for the two epochs using repeated-measures ANOVA to com-
pare the groups. The decision was made a priori to include 
any subject in these analyses if that patient had taken at least 
one week’s worth of drug during an epoch and returned for a 
follow-up visit. A secondary post hoc analysis of the data from 
trial completers was also performed across all three visits us-
ing repeated-measures ANOVA. Statistical computations used 




A total of 24 patients were enrolled (see Figure 1). Though the 
original study design sought enrollment of 30 patients, the 
Figure 1. CONSORT flowchart.
Table 1. Summary of final study design.









Clinical evaluation; return to 
routine clinical care
This table summarizes the study design and timing of assessments and interventions for the last 19 subjects enrolled in the 
study. ↑ dopaminometic: dose increase allowed for antiparkinsonian medication, if parkinsonism had worsened since starting 
the study. See Methods and Figure 1 for further details.
Assessed for eligibility (n=24)
Randomized (n=24)
Analyzed (n=9)






Discontinued due to motor 
SEs (n=1)




Allocated to 2.5mg 
 (n=6)
Allocated to  5mg 
 (n=8)






due to lack of f/u (n=2)
Analyzed (n=0)
Excluded from analysis




due to lack of f/u (n=3)
Allocated to & received 
placebo (n=9)
Discontinued placebo
due to death (n=1)
Discontinued due to
lack of efficacy (n=1)
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study was terminated early, secondary to the growing body 
of literature questioning the safety of olanzapine in the treat-
ment of DIP as well as the increasing difficulty in enrolling 
antipsychotic-naive patients.
Only one subject was treated with 10mg (one other was rand-
omized to the 10mg group, but was treated only for one week, 
so received only 5mg doses). His hallucinations were rated 
“very much improved” at the study end; he required no adjust-
ment in dopaminomimetic dose mid-study and no side effects 
were observed. This 10mg subject was not included in statisti-
cal analyses. In the remaining 23 subjects, no significant imbal-
ances were present at baseline between placebo and treatment 
groups on any demographic characteristic or any psychiatric or 
neurologic measure (Table 2).
Intention-to-treat analyses
The intention-to-treat analyses did not show significant differ-
ences between groups except for incidence of mild side effects 
(p<0.04) (Table 3). While spontaneous report of motor side 
effects was not statistically significant between groups, a dis-
proportionate number of olanzapine vs. placebo group subjects 
who withdrew did so secondary to reported motor side effects 
(0% of placebo withdrawers vs. 21% of olanzapine withdraw-
ers). Nine subjects did not complete the study: two from the 
placebo group, four from the 2.5mg olanzapine group, and 
three from the 5mg olanzapine group. In the placebo group, 
one patient died of myocardial infarction and another with-
drew from the study secondary to lack of efficacy. In the 5mg 
olanzapine group, two reported serious adverse events and a 
third discontinued her medication following the first dose, de-
claring herself “cured”. Of the 5mg subjects who withdrew for 
serious adverse events, one was hospitalized with delirium three 
weeks into the study; the other withdrew after day six due to 
hospitalization with hip fracture and pneumonia, and reported 
worsening PD symptoms prior to dropout. Of the four subjects 
who dropped out of the 2.5mg olanzapine group, two with-
drew due to worsening parkinsonian symptoms, one second-
ary to unspecified side effects, and one secondary to “feeling 
confused”. Only two subjects in the 2.5mg group completed 
the study, both requiring increases of their levodopa dose at 
their interim visit. One each in the placebo and 5mg olanzap-
ine arms also required levodopa adjustment at their two-week 
assessment. Retention and attrition of study subjects is sum-
marized in Table 3 and Figure 1.
To assess adequacy of blinding, both the primary investigator 
and study subjects were asked on study completion (or drop-
out) to guess the identity of administered medication (i.e., olan-
zapine vs. placebo). Both investigator and patient were much 
more likely than chance would predict to correctly guess the 
identity of administered medication (for investigator, χ2=12.29, 
p=0.0021; for study subjects, χ2=6.94, p=0.0312). However, 
the videotape rater had no information about side effects.
Negative results from a randomized controlled trial of olanzapine 
for psychosis in Parkinson disease: data, CONSORT checklist 




Analysis of the psychosis subscale of BPRS scores (the more 
sensitive of our primary efficacy measures) did not reveal a sta-
tistically significant difference between groups (drug doses) in 
severity of psychosis in either the week 0–2 epoch (p=0.433) or 
the week 2–4 epoch (p=0.393). Again, post hoc analysis in study 
completers revealed no statistical significance in psychosis re-
duction between olanzapine (combined groups) and placebo 
(p=0.536), as shown in Figure 2.
Data from the first and second epochs revealed no statistically 
significant difference in parkinsonian signs across treatment 
groups, as measured by the UPDRS III (week 0–2 epoch, pla-
cebo vs. 2.5mg olanzapine group p=0.172; week 2–4 epoch 
p=0.677). Post hoc analysis of UPDRS motor scores comparing 
olanzapine (combined groups) versus placebo across the dura-
tion of study found no significant difference in parkinsonism 
among study completers (p=0.608) (Figure 3).
Analyses were repeated in like fashion for all other psychiatric 
and neurological parameters (CGI impression, CGI improve-
Table 2. Patient characteristics at baseline.
Olanzapine
Measure Placebo (n=9) 2.5mg (n=6) 5mg (n=8) p value
Age 71.3 (6.5) 70.7 (8.1) 72.4 (4.8) 0.882
MMSE 26 (2.6) 27 (3.6) 27 (2.7) 0.976
BPRS-T 34.8 (5.9) 34.3 (5.4) 33.4 (3) 0.874
BPRS-P 7.9 (2) 9 (3) 7.8 (2.1) 0.633
UPDRS, 
motor score 30 (11) 27.5 (13.1) 31 (11.6) 0.855
PDQ-39 53 (25.7) 59 (15.9) 59 (27.3) 0.867
BDI 10.1 (6) 9.8 (6) 12.6 (9.2) 0.738
HAM-D 8.7 (6.1) 5.3 (1.6) 11.6 (7.6) 0.177
CGI 4.1 (0.9) 3.2 (1) 3.9 (0.8) 0.161
INS 4.2 (4) 4 (2.1) 2.6 (2.6) 0.566
HYPINS 1.5 (1) 2.3 (1.9) 2.6 (2.1) 0.446
SEADL 76 (15) 72 (24) 75 (17) 0.918
Values are given as mean (SD). MMSE, Folstein mini mental test examination; 
BPRS-T, Brief Psychiatric Rating Scale total score; BPRS-P, psychosis 
subscale; UPDRS, Unified Parkinson’s Disease Rating Scale; PDQ-39, 
Parkinson’s disease quality of life questionnaire; BDI, Beck depression 
inventory; HAM-D, Hamilton depression rating scale; CGI, Clinical global 
impression; INS, Insomnia score; HYP, Hypersomnia score; SEADL,  
Schwab-England ADL assessment.
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ment, BPRS total, BDI, MMSE, insomnia score, hypersomno-
lence score, PDQ-39, and Schwab-England ADL assessment), 
none of which revealed statistical significance between olanzap-
ine groups and placebo.
Discussion
The study failed to reject the null hypothesis. This could be a Type 
II error, but larger studies of olanzapine also failed to demonstrate 
antipsychotic efficacy of this drug in the PD population14,33. In 
study completers, we did not observe the motoric exacerbation 
documented in several studies in the literature28–34, but perhaps 
this is a function of our allowance for dopaminomimetic increase 
mid-study as well as a selection bias in some analyses for those sub-
jects who best tolerated the medication and therefore completed the 
study. After all, of the nine subjects who withdrew from the study, 
a third identified a worsening of their motor disability prior to 
dropout, all of whom were discovered on unblinding to have been 
randomized to olanzapine. Therefore the good retrospective 
accuracy of investigator and patient guesses of study drug identity 
is not surprising.
The subjects enrolled are relatively typical of PD patients with 
psychotic symptoms with a few exceptions. Subjects with urgent 
need for treatment were not enrolled for ethical reasons. Although 
mild dementia was allowed, this sample had relatively high cogni-
tive functioning, with a mean MMSE score > 26 (Table 2). Final-
ly, at this center, some of the patients are referred for subspecialty 
movement disorders consultation, though a large fraction of the 
patients are not referred and are typical of PD patients treated in 
the community. With these caveats, the results appear to be gen-
erally applicable to patients with PD and psychosis.
One methodological innovation in this study was the use of 
videotape to record semi-standardized interviews for later 





























Week 2 Week 4
Figure 2. Brief Psychiatric Rating Scale (BPRS) scores across 
four week study revealed no significant difference between 
placebo and olanzapine groups among study completers. 
Current effect: F(2, 24)=0.64064, p=0.53573. Effective hypothesis 
decomposition. Vertical bars denote 0.95 confidence intervals. 
Olanzapine-blue; placebo-red.
Table 3. Subject retention and side effects by group.
Olanzapine
Placebo 2.5mg 5mg All p value
# enrolled 9 6 8 23
# withdrew 2 (22%) 4 (66%) 3 (38%) 9 (39%) 0.2232
# withdrew for motor SEs 0 (0%) 2 (33%) 1 (12%) 3 (13%) 0.1712
# w/motor SE complaint 1 (11%) 2 (33%) 1 (12%) 4 (17%) 0.4863
# w/any mild SEs 2 (22%) 5 (83%) 2 (25%) 9 (39%) *0.0356
# w/serious adverse 
events 1 (11%) 0 (0%) 2 (25%) 3 (13%) 0.3795
# included in 1st epoch 9 (100%) 3 (50%) 5 (63%) 17 (74%) 0.0640
# included in 2nd epoch 7 (78%) 2 (33%) 5 (63%) 14 (61%) 0.2232
# w/dopaminomimetic ↑ 1 (11%) 2 (33%) 1 (13%) 4 (17%) 0.4863
Side effects (SEs) were any complaint of drug spontaneously reported by the patient, 
independent of whether SE intensity was severe enough to prompt withdrawal from the 
study. Serious adverse events always prompted withdrawal. SE, side effects; ↑, increase; 




























Week 2 Week 4
Figure 3. Unified Parkinson’s Disease Rating Scale (UPDRS) 
scores across four week study revealed no significant 
difference between placebo and olanzapine groups among 
study completers. Current effect: F(2, 24)=0.50826, p=0.60787. 
Effective hypothesis decomposition. Vertical bars denote 0.95 
confdence intervals. Olanzapine-blue; placebo-red.
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collection. KJB designed the study, supervised all aspects of the 
study, takes responsibility for all aspects of the manuscript, and 
performed 40% of data analysis, 40% of data collection, and 
30% of manuscript preparation. All authors reviewed the manu-
script.
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we and others have not replicated the early, positive open-
label experience reported for olanzapine in this population. 
If clozapine’s prominence in the clinical management of DIP 
in PD is to be usurped, antipsychotic agents will have to 
meet the burden of proof of double-blind, randomized, 
placebo-controlled trials.
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Guidelines for rating selected BPRS items in a treatment 
study of psychosis in Parkinson disease.
1.  Emotional withdrawal = interpersonal relatedness during 
interview.
2. Tension:
 a.  Ignore: rest tremors, postural tremors, chorea, athetosis, 
dystonia.
 b. Include: tardive dyskinesia and akathisia.
3.  Depressive mood rating does not consider “pure apathy” 
(i.e., apathy w/o other depressive signs or symptoms), but 
apathy can contribute to the total judgment of depressive 
mood if other signs or symptoms are present.
4. Hallucinatory behavior:
 a. 2 = illusions and “shadow in the corner of the eye”.
 b. 3 = e.g., colors on the wall.
 c. ≥ 4 = definitively abnormal sensory perceptions.
5.  Motor retardation: Speed of movement, not amplitude 
(also, depressive retardation is not substantially helped by 
external cues; if slowed movement is substantially helped 
by external cues, then it may be more parsimoniously 
attributed to PD).
6.  Unusual thought content: Ratings ≥ 5 require action on 
delusion.
7.  Blunted affect: Rate according to scale, considering emo-
tional variance, regardless of amplitude; remember that 
flat/blunted affect is not equivalent to depressed affect.
8.  Disorientation: Off by one day of week = 3. 
   Motor hyperactivity: Limit rating to pressured speech and 
voluntary movement; festination does not count. 
Kevin J Black MD consulted with John G Csernansky MD 
to write these additional rules for scoring BPRS items po-
tentially influenced by motor signs in Parkinson disease 
patients.
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The study (completed in 2003) was well designed, albeit with a relatively small sample size, and
intended to answer an important and clinically relevant question.  After reviewing the manuscript I would
agree that it probably does support the notion that olanazapine may cause intolerable worsening of
motor disability but I do not think that one can draw any conclusions regarding efficacy or lack thereof
based on this study.  
 
One element of the trial design (i.e. permitting changes in dopaminergic medications) may have created
some challenges when interpreting the data.  The investigators speculated that olanzapine may be
better tolerated if adjustments in dopaminergic medications were allowed (and therefore permitted
dopaminergic medication adjustment at the 2 week visit).  While this may be true, it could also increase
the chances that dopaminergic drug induced psychosis could worsen (if dopaminergic medication were
increased in an effort to improve motor worsening).  This could potentially be a "set up" for decreased
efficacy (if dopaminergic medications were changed more frequently in active vs. placebo).  It is noted
that medications were adjusted in one of the placebos, two of the 2.5 mg active and one of the 5 mg
active.  The authors note that there was an apriori decision to analyze data from weeks 0-2 and 2-4
separately.  Change from 0-2 weeks was chosen to be the primary test of efficacy, apparently in order to
limit the confound of changes in dopaminergic medications allowed at week two.  However, one could
question if 2 weeks is long enough to demonstrate efficacy.   
 
In addition, a series of unplanned events contributed to challenges with data interpretation. These
events included a change in design after study initiation, lower than expected enrollment and high
dropout rate.
 
The change in study design was a decrease in study drug dosage after enrollment of 5 subjects ("in light
of reports published since study initiation that higher olanzapine doses cause intolerable exacerbation of
parkinsonism in PD").  This resulted in one subject being excluded from analyses (see below) and
perhaps, decreased the chance of demonstrating study drug efficacy (if higher dosages were required).  
 
Only 24 (of an anticipated 30) subjects were enrolled and 9 withdrew (39%) which is a fairly high dropout
rate.  One of the 24 subjects was not included in the analyses because he was the only one to receive
the initially planned dosage of 10 mg.  
 
While spontaneous reports of motor side effects were not statistically significant between groups, a
disproportionate number of olanzapine vs. placebo who withdrew did so due to motor side effects.  This
finding does suggest that olanzapine may be associated with worsening motor function.  However this
may not be true for every patient, as exemplified by the one subject who was the only to receive the
initially planned dosage of 10 mg.  He had no worsening of motor function (and an improvement in
psychosis).
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